Last update 31 Mar 2025

YL-201

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
YL 201, YL201
Action
modulators, inhibitors
Mechanism
CD276 modulators(CD276 antigen modulators), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Breakthrough Therapy (China)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nasopharyngeal CarcinomaPhase 3
China
25 Dec 2024
Recurrent Lung Small Cell CarcinomaPhase 3
China
06 Dec 2024
Metastatic castration-resistant prostate cancerPhase 2
China
22 Feb 2024
Advanced Malignant Solid NeoplasmPhase 2
China
28 Sep 2023
Esophageal Squamous Cell CarcinomaPhase 2
China
22 Sep 2023
Hepatocellular CarcinomaPhase 2
China
22 Sep 2023
Non-Small Cell Lung CancerPhase 2
China
22 Sep 2023
Pancreatic Ductal AdenocarcinomaPhase 2
China
22 Sep 2023
Squamous Cell Carcinoma of Head and NeckPhase 2
China
22 Sep 2023
Extensive stage Small Cell Lung CancerPhase 1
United States
13 Mar 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
29
usxfqpcjkl(qgyhgytwyf) = cozfupkfae kbdnbobypm (tyipzvxdsw )
Positive
26 Mar 2025
Phase 3
438
vmaglqoztl(wayhqbdypn) = zqxjisjaiq apdggepuer (fsshzhnhqp )
Positive
26 Sep 2024
(SCLC)
vmaglqoztl(wayhqbdypn) = brdsbrkixi apdggepuer (fsshzhnhqp )
Phase 1
276
ljtlxugofs(jltsuiwssp) = leukopenia (52.9%; grade [G]≥3: 22.5%), anemia (51.1%; G≥3: 14.9%) and neutropenia (48.9%; G≥3: 23.9%) baygehqusj (ykwlciycmj )
Positive
13 Sep 2024
YL201 2.0 mg/kg
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free